Elisabeth Leiderman
Director/Board Member at BLUEBIRD BIO, INC.
Net worth: 20 097 $ as of 2024-05-30
Network origin in Elisabeth Leiderman first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 35 | |
| Public Company | Biotechnology | 23 | |
| Public Company | Pharmaceuticals: Major | 21 | |
| Public Company | Biotechnology | 12 | |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.
9
| Extinct | Pharmaceuticals: Major | 9 |
Nomura Securities, Inc.
3
| Private Company | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Elisabeth Leiderman via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| 2SEVENTY BIO, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chairman Chairman Chief Executive Officer Director/Board Member Director/Board Member Investor Relations Contact Director/Board Member Director/Board Member Director/Board Member | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Founder | |
| University of Pennsylvania | College/University | Graduate Degree Undergraduate Degree Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Director of Finance/CFO Comptroller/Controller/Auditor Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| CHECKPOINT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Corporate Secretary | |
| University of Cambridge | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Director/Board Member Chairman Corporate Officer/Principal Corporate Officer/Principal | |
| AVENUE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Corporate Secretary | |
| MUSTANG BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director of Finance/CFO Corporate Secretary | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Founder Chief Executive Officer Chairman Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member General Counsel | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer Chairman Director/Board Member | |
| VERASTEM, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer Chief Executive Officer | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | President Corporate Officer/Principal Corporate Officer/Principal | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Yale University | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Biotechnology | Director/Board Member Founder Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GENTIUM S.P.A. (ADR) | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| TG THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member | |
| ORIGO ACQUISITION CORP | Financial Conglomerates | Chief Executive Officer Chairman Chief Operating Officer | |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of California, Los Angeles | College/University | Corporate Officer/Principal Graduate Degree Undergraduate Degree | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| New York University | College/University | Undergraduate Degree Undergraduate Degree | |
| ANNEXON, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| CHINOOK THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Cellvation, Inc. | Chairman Director/Board Member | ||
| Columbia Law School | College/University | Graduate Degree Graduate Degree | |
| Brown University | College/University | Undergraduate Degree Undergraduate Degree | |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Medical Specialties | Chairman Corporate Officer/Principal | |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Miscellaneous Commercial Services | Founder Founder | |
| CHAMPIONS ONCOLOGY, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| The Johns Hopkins University | College/University | Graduate Degree Graduate Degree |
Statistics
International
| United States | 43 |
| United Kingdom | 5 |
| Switzerland | 3 |
| Italy | 2 |
| Norway | 2 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 12 |
| Finance | 3 |
| Commercial Services | 3 |
| Health Services | 2 |
Operational
| Director/Board Member | 502 |
| Corporate Officer/Principal | 233 |
| Independent Dir/Board Member | 169 |
| Chairman | 111 |
| Chief Executive Officer | 86 |
Most connected contacts
| Insiders | |
|---|---|
| John Johnson | 40 |
| Kapil Dhingra | 39 |
| Peter Thompson | 39 |
| Eric Rowinsky | 36 |
| Martin Murphy | 33 |
| Daniel Lynch | 32 |
| William Young | 32 |
| Bobby Sandage | 29 |
| Malcolm Hoenlein | 28 |
| Wendy Dixon | 25 |
| Michael Weiss | 25 |
| John Berriman | 24 |
| Lindsay Rosenwald | 23 |
| Sara Nayeem | 23 |
| Karin Hehenberger | 21 |
- Stock Market
- Insiders
- Elisabeth Leiderman
- Company connections
